title: Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey.
abstract: OBJECTIVE
  Hepatitis A is among the diseases that can be prevented with vaccination in our time. Acute hepatitis A progresses more severely in individuals with a liver disease. Therefore, patients with a chronic liver disease (because of hepatitis B or hepatitis C) are advised vaccination with the hepatitis A vaccine. This study is aimed to determine the seroprevalence of hepatitis A virus (HAV) antibodies in patients infected with hepatitis C virus or hepatitis B virus in Konya province of Turkey.
  
  
  METHODS
  A total of 537 patients who had chronic viral hepatitis between January 2011 and December 2014 were included in the study. Serum samples were collected from each patient and tested for anti-HAV using the chemiluminescent microparticle immunoassay.
  
  
  RESULTS
  The overall seroprevalence of total anti-HAV IgG was 94.2%. The overall prevalence of anti-HAV IgG in patients with chronic hepatitis B virus and hepatitis C virus infection was 97.5 and 93.6%, respectively. Anti-HAV IgG positivity was 97.4% in cirrhotic patients and 93.9% in noncirrhotic individuals.
  
  
  CONCLUSIONS
  At the end of the study, being older than 40 years and living in a rural area were found to be independent risk factors for anti-HAV IgG seropositivity. In conclusion, we recommend that patients younger than 40 years and/or those living in cities and having a chronic liver disease should be vaccinated with the hepatitis A vaccine.
authors.affiliation: Infectious Diseases and Clinical Microbiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey.
authors.forename: Hale T
authors.initials: HT
authors.lastname: Özden
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D060085:Coinfection; D005260:Female; D006506:Hepatitis A / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D035922:Hepatitis A Antibodies / Q000097:blood*; D030041:Hepatitis A virus / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D012423:Rural Health; D016036:Seroepidemiologic Studies; D014421:Turkey / Q000453:epidemiology; D014504:Urban Health; D055815:Young Adult
chemical_list: D035922:Hepatitis A Antibodies; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007074:Immunoglobulin G; D012367:RNA, Viral